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obstructive pulmonary disease; Gof Acute Myocardial InfarctionTo the Editor: Survivors of acute myocardial infarction (MI) are at
substantial risk of subsequent death due to progressive heart failure,
arrhythmic events, and/or reinfarction. We have recently shown
that respiratory rate measured in 10-min supine position by a
piezoelectric thoracic sensor provides powerful and independent
prognostic information in these patients (1). The goal of this study
was to assess the prognostic potential of the nocturnal respiratory
rate (NRR), assessed from standard Holter electrocardiogram re-
cordings in a larger patient cohort. Additionally, we analyzed the
association of NRR and different death modes, especially sudden
(SCD) and non–sudden cardiac death (N-SCD).
Data from the previously reported cohort (1) were used to
develop an algorithm deriving the NRR from Holter recordings,
and to determine NRR optimum risk-predicting dichotomy
of 18.6/min. Brieﬂy, the algorithm determines the respiration
rate from QRS amplitudes, QRS vectors, and heartbeat intervals,
all of which are inﬂuenced by respiration. NRR was subsequently
prospectively assessed in 1,538 MI survivors enrolled between 1996
and 2005 in 2 Munich centers. Standard Holter electrocardiograms
were recorded at a median of 5 days (interquartile range: 4 to 7
days) after MI. The primary study endpoint was 5-year cardiac
mortality. Secondary endpoints were N-SCD, SCD, all-cause
mortality, and noncardiac mortality. An independent endpoint
committee assigned the modes of death. The study was approved
by the local ethics committee.CD
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RACE ¼ Global Registry of Acute Coronary Events.Within the ﬁrst 5 years, 146 patients (9.5%) died. Of these,
82 patients suffered cardiac deaths (39 N-SCD and 43 SCD) and
64 noncardiac deaths.
NRR was 18.6/min in 384 patients and <18.6/min in 1,154
patients. Five-year cardiac mortality rates in these groups were
13.7% and 3.3%, respectively (p < 0.001). In multivariable Cox
analysis, cardiac mortality and N-SCD, but not SCD, were
signiﬁcantly associated with NRR (Fig. 1A). NRR 18.6/min
indicated a hazard ratio for N-SCD of 4.56 (95% conﬁdence in-
terval: 2.21 to 9.43; p < 0.001). The association of NRR and
N-SCD was independent from established Holter-based parame-
ters of cardiac autonomic function such as heart rate variability
parameters or heart rate turbulence.
A total of 155 patients had left ventricular ejection fraction
(LVEF) 35%. Of these, 64 had an NRR <18.6/min, and 91
had an NRR 18.6/min. In the group of patients with
NRR <18.6/min, cardiac mortality was 12.5%, 3.1% attributable
to N-SCD and 9.4% attributable to SCD. In the group of
patients with NRR 18.6, cardiac mortality was 28.6%, 16.5%
attributable to N-SCD, and 12.1% attributable to SCD. Differ-
ences were statistically signiﬁcant for cardiac mortality and N-SCD
(p < 0.001 and p ¼ 0.009, respectively), but not for SCD
(p ¼ 0.595). Figure 1B depicts the proportions of N-SCD among
all cardiac deaths as a function of the LVEF and NRR
dichotomies.nalyses are shown for non–sudden cardiac death (N-SCD) and sudden cardiac death
al respiratory rate (NRR) dichotomies, proportions of N-SCD among all cardiac deaths
patients with LVEF below and NRR above the respective threshold. COPD ¼ chronic
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2433We assume that increased NRR is an early sign of impending
heart failure prompted by either subclinical pulmonary congestion
or by altered autonomic control of respiratory activity (1). We
foresee potential roles of NRR for future risk stratiﬁcation ap-
proaches. Currently, LVEF is the mainstay of post-MI risk
assessment, as the decision whether to implant a deﬁbrillator is
based mainly on LVEF. NRR might prove helpful by identi-
fying patients who are less likely to beneﬁt from ICD implantation
because of a high N-SCD prevalence. Among patients with
LVEF 35% (i.e., ICD candidates), increased NRR identiﬁes a
group of patients with frequent N-SCD (i.e., a mode of death likely
not implantable cardioverter-deﬁbrillator [ICD] preventable).
Moreover, it cannot be excluded that ICD implantation might be
harmful in some of these patients.
Independent validation of this new risk stratiﬁcation approach
is necessary before it can be incorporated into clinical decision
making. Most importantly, the post-hoc assigned cause-speciﬁc
mortalities can only provide an approximation of deaths that may
and may not be prevented by ICD implantation. While a deﬁnite
proof of the hypothesis would require a prospective study per-
formed in ICD candidates, the methodology presented here also
allows for independent conﬁrmatory analyses in datasets from ICD
primary prevention studies, provided that digitized Holter re-
cordings are available.Michael Dommasch, MDy
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2013;34:1644–50.Letters to the EditorBaroreﬂex Sensitivity
and Renal Sympathetic
Denervation
We read with great interest the study by Zuern et al. (1) about the
possibility of predicting for the ﬁrst time the response to renal
sympathetic denervation (RDN) in patients with resistant hyper-
tension, using cardiac baroreﬂex sensitivity (BRS).
This fascinating report demonstrates that 1) the antihypertensive
effect of RDN was greater in patients with impaired BRS, and
2) this effect was associated with restoration of BRS after the
procedure. These positive results were obtained with BRS measured
in 2 ways, namely, the classical sequence method (BRSseq) and the
bivariate phase rectiﬁed signal averaging method (BRSprsa). In this
study of 50 patients, analysis of receiver operating characteristic
(ROC) curves showed that BRSprsa was a better predictor of the
hypotensive effect of RDN than BRSseq. Consequently, the in-
vestigators focused the rest of the analysis on BRSprsa using a
more complex and accurate predictive model. It would, neverthe-
less, be a pity at this stage of RDN development to ignore BRSseq,
which is the only BRS measurement technique that beneﬁts from
prognostic data in patients with hypertension. The EVABAR
(Evaluation of the Prognostic Value of Baroreﬂex Sensitivity in
Hypertensive Patients) study, which investigated a cohort of 451
patients with hypertension with no particular history who were
followed for an average of 6.2 years, demonstrated the prognostic
role of BRSseq for cardiovascular events (2). Using a BRS mea-
surement technique that beneﬁts from prognostic data is all the
more relevant because there does not currently exist any method of
identifying those patients with hypertension whose prognosis
might be improved by RDN (above and beyond lower blood
pressure).
In addition, the accompanying editorial (2) emphasized the
fact that BRS was not uniformly predictive for all patients with
hypertension nor did it predict the magnitude of blood pressure
reduction. The results of Zuern et al. (1) would suggest that
the value of higher-resolution analysis of BRS was to determine
whether the sympathetic component on its own or the sympathetic/
parasympathetic balance would improve prediction of the efﬁcacy
of RDN on blood pressure. Distinguishing between BRSseq “up”
and “down” sequences would make it easier to weigh the sympa-
thetic and parasympathetic contributions (3,4).*Olivier Ormezzano, MD, PhD
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